Fig. 3: Inhibition of mTOR signaling ameliorates ATF3 deficiency-mediated liver damage in IR-induced liver injury. | Cell Death & Disease

Fig. 3: Inhibition of mTOR signaling ameliorates ATF3 deficiency-mediated liver damage in IR-induced liver injury.

From: Loss of ATF3 exacerbates liver damage through the activation of mTOR/p70S6K/ HIF-1α signaling pathway in liver inflammatory injury

Fig. 3

Mice were injected with the mTOR inhibitor rapamycin (Rap) or DMSO vehicle at 60 min prior to ischemia. a Representative histological staining (H&E, original magnification ×100) and TUNEL staining of ischemic liver tissue (4–6 mice/group). b Liver damage, as evaluated by Suzuki’s score. ***p < 0.001. TUNEL staining, results were scored semi-quantitatively by averaging the number of apoptotic cells (mean ± SD) per field at ×400 magnification. ***p < 0.001. c Hepatocellular function, as assessed by serum ALT levels (IU/L). Results are expressed as the mean ± SD (n = 4–6 samples/group). ***p < 0.001. d Liver CD11b+ macrophages and Ly6G+ neutrophils were detected by immunohistochemistry. Results were scored semi-quantitatively by averaging the number of positively stained cells (mean ± SD)/field at ×400 magnification. Representative of 4–6 mice/group. ***p < 0.001. e Western blot analysis of phosphorylated mTOR, phosphorylated p70S6K, PHD1, HIF-1α, HMGB1, and TLR4. β-actin served as an internal control. Data are representative of three experiments. f Quantitative RT-PCR-assisted detection of TNF-α, IL-1β, IL-6, and TGF-β expression. Mean ± SD (n = 3–4 samples/group). *p < 0.05

Back to article page